Hepatitis C virus virology and new treatment targets

Expert Review of Anti-Infective Therapy

Volumn 7, Issue 3, 2009, Pages 329-350

  Meier, Volker ^a   Ramadori, Giuliano ^a  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

Fibrosis; Paparoscopy; Pegylated IFN ; Polymerase inhibitor; Ribavirin; SiRNA; STAT C

Indexed keywords

4' AZIDOCYTIDINE; 4' AZIDOCYTIDINE 2',3',5' TRIISOBUTYRATE; 5 CYCLOPROPYL 2 (4 FLUOROPHENYL) 6 [N (2 HYDROXYETHYL)METHANESULFONAMIDO] N METHYLBENZOFURAN 3 CARBOXAMIDE; ACH 806; ALPHA INTERFERON; ALPHA2 INTERFERON; ANA 598; ANTIINFECTIVE AGENT; ANTIVIRUS AGENT; B 201335; BILB 1941; BLX 883; BOCEPREVIR; CILUPREVIR; GS 9132; GS 9190; INTERFERON; ITMN 191; LOCTERON; MAXY ALPHA; OMEGA INTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PF 0086554; PSI 6130; R 7025; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; TARIBAVIRIN; TELAPREVIR; TMC 435350; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALOPICITABINE; ENZYME INHIBITOR;

ABSENCE OF SIDE EFFECTS; ANEMIA; ANTIVIRAL ACTIVITY; CANCER RISK; CLINICAL TRIAL; DISEASE COURSE; DNA POLYMORPHISM; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; DRUG SCREENING; DRUG TARGETING; DRUG TOLERABILITY; DRUG TOXICITY; DRUG TREATMENT FAILURE; GASTROINTESTINAL DISEASE; GENE ACTIVATION; GENE EXPRESSION; GENOTYPE; HEPATITIS C; HUMAN; IMMUNOPATHOGENESIS; INFECTION RATE; LIVER CELL CARCINOMA; LOW DRUG DOSE; NAUSEA; NEUTROPENIA; NONHUMAN; PREVALENCE; REVIEW; RISK REDUCTION; TARGET ORGAN TOXICITY; TOXICITY; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; UPREGULATION; VIRUS LOAD; VIRUS REPLICATION; VOMITING; CLASSIFICATION; DRUG EFFECT; ENZYMOLOGY; GENETICS; HEALTH; HEPATITIS C VIRUS; VIROLOGY;

ANTIVIRAL AGENTS; CLINICAL TRIALS AS TOPIC; ENZYME INHIBITORS; HEPACIVIRUS; HEPATITIS C; HEPATITIS C, CHRONIC; HUMANS; PREVALENCE; WORLD HEALTH;

EID: 67649095226     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/ERI.09.12     Document Type: Review

References (229)

1. Feinstone SM, Kapikian AZ, Purcell RH, Alter HJ, Holland PV. Transfusion-associated hepatitis not due to viral hepatitis type A or B. N. Engl. J. Med. 292(15), 767-770 (1975).
2. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244(4902), 359-362 (1989).
3. Alter HJ, Purcell RH, Shih JW et al. Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. N. Engl. J. Med. 321(22), 1494-1500 (1989).
4. Alter HJ, Houghton M. Hepatitis C virus and eliminating post-transfusion hepatitis. Nat. Med. 6, 1082-1086 (2000).
5. Global burden of disease (GBD) for hepatitis C. J. Clin. Pharmacol. 44(1), 20-29 (2004).
6. Frank C, Mohamed MK, Strickland GT et al. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet 355(9207), 887-891 (2000).
7. Shepard CW, Finelli L, Fiore AE, Bell BP. Epidemiology of hepatitis B and hepatitis B virus infection in United States children. Pediatr. Infect. Dis. J. 24(9), 755-760 (2005).
8. Strickland GT. Liver disease in Egypt: hepatitis C superseded schistosomiasis as a result of iatrogenic and biological factors. Hepatology 43(5), 915-922 (2006).
9. Alter MJ. Epidemiology of hepatitis C virus infection. World J. Gastroenterol. 13(17), 2436-2441 (2007).
10. Alter MJ. Epidemiology of hepatitis C. Hepatology 26(3 Suppl. 1), 62-65 (1997).
11. Zeuzem S, Teuber G, Lee JH, Ruster B, Roth WK. Risk factors for the transmission of hepatitis C. J. Hepatol. 24(2), 3-10 (1996).
12. Conry-Cantilena C, VanRaden M, Gibble J et al. Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection. N. Engl. J. Med. 334(26), 1691-1696 (1996).
13. Touzet S, Kraemer L, Colin C et al. Epidemiology of hepatitis C virus infection in seven European Union countries: a critical analysis of the literature. HENCORE Group. (Hepatitis C European Network for Co-operative Research). Eur. J. Gastroenterol. Hepatol. 12(6), 667-678 (2000).
14. Delage G, Infante-Rivard C, Chiavetta JA, Willems B, Pi D, Fast M. Risk factors for acquisition of hepatitis C virus infection in blood donors: results of a case - control study. Gastroenterology 116(4), 893-899 (1999).
15. Resti M, Azzari C, Mannelli F et al. Mother to child transmission of hepatitis C virus: prospective study of risk factors and timing of infection in children born to women seronegative for HIV-1. Tuscany Study Group on Hepatitis C Virus Infection. BMJ 317(7156), 437-441 (1998).
16. Gibb DM, Goodall RL, Dunn DT et al. Mother-to-child transmission of hepatitis C virus: evidence for preventable peripartum transmission. Lancet 356(9233), 904-907 (2000).
17. Prieto M, Olaso V, Verdu C et al. Does the healthy hepatitis C virus carrier state really exist? An analysis using polymerase chain reaction. Hepatology 22(2), 413-417 (1995).
18. Silini E, Bono F, Cividini A et al. Differential distribution of hepatitis C virus genotypes in patients with and without liver function abnormalities. Hepatology 21(2), 285-290 (1995).
19. Sangiovanni A, Morales R, Spinzi G et al. Interferon α treatment of HCV RNA carriers with persistently normal transaminase levels: a pilot randomized controlled study. Hepatology 27(3), 853-856 (1998).
20. Assy N, Minuk GY. Serum aspartate but not alanine aminotransferase levels help to predict the histological features of chronic hepatitis C viral infections in adults. Am. J. Gastroenterol. 95(6), 1545-1550 (2000).
21. Wietzke-Braun P, Braun F, Schott P, Ramadori G. Is laparoscopy an advantage in the diagnosis of cirrhosis in chronic hepatitis C virus infection? World J. Gastroenterol. 9(4), 745-750 (2003).
22. Di Bisceglie AM. Hepatitis C and hepatocellular carcinoma. Semin. Liver Dis. 15, 64-69 (1995).
23. Degos F, Christidis C, Ganne-Carrie N et al. Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death. Gut 47(1), 131-136 (2000).
24. Charlton M, Seaberg E, Wiesner R et al. Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology 28(3), 823-830 (1998).
25. Takaki A, Wiese M, Maertens G et al. Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nat. Med. 6(5), 578-582 (2000).
26. Barrett S, Ryan E, Crowe J. Association of the HLA-DRB1*01 allele with spontaneous viral clearance in an Irish cohort infected with hepatitis C virus via contaminated anti-D immunoglobulin. J. Hepatol. 30(6), 979-983 (1999).
27. Robertson B, Myers G, Howard C et al. Classification, nomenclature, and database development for hepatitis C virus (HCV) and related viruses: proposals for standardization. International Committee on Virus Taxonomy. Arch. Virol. 143(12), 2493-2503 (1998).
28. Simmonds P, Bukh J, Combet C et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 42(4), 962-973 (2005).
29. Laperche S, Lunel F, Izopet J et al. Comparison of hepatitis C virus NS5b and 5′ noncoding gene sequencing methods in a multicenter study. J. Clin. Microbiol. 43(2), 733-739 (2005).
30. Laperche S, Saune K, Deny P et al. Unique NS5b hepatitis C virus gene sequence consensus database is essential for standardization of genotype determinations in multicenter epidemiological studies. J. Clin. Microbiol. 44(2), 614-616 (2006).
31. Esteban JI, Sauleda S, Quer J. The changing epidemiology of hepatitis C virus infection in Europe. J. Hepatol. 48(1), 148-162 (2008).
32. Nguyen MH, Keeffe EB. Prevalence and treatment of hepatitis C virus genotypes 4, 5, and 6. Clin. Gastroenterol. Hepatol. 3(10 Suppl. 2), S97-S101 (2005).
33. Ramia S, Eid-Fares J. Distribution of hepatitis C virus genotypes in the Middle East. Int. J. Infect. Dis. 10(4), 272-277 (2006).
34. Rustgi VK. The epidemiology of hepatitis C infection in the United States. J. Gastroenterol. 42(7), 513-521 (2007).
35. Huang L, Koziel MJ. Immunology of hepatitic C virus infection. Curr. Opin. Gastroenterol. 16, 558-564 (2000).
36. Schweyer S, Mihm S, Radzun HJ, Hartmann H, Fayyazi A. Liver infiltrating T lymphocytes express interferon γ and inducible nitric oxide synthase in chronic hepatitis C virus infection. Gut 46(2), 255-259 (2000).
37. Baroni GS, Pastorelli A, Manzin A et al. Hepatic stellate cell activation and liver fibrosis are associated with necroinflammatory injury and Th1-like response in chronic hepatitis C. Liver 19(3), 212-219 (1999).
38. Ksontini R, Colagiovanni DB, Josephs MD et al. Disparate roles for TNF-α and Fas ligand in concanavalin A-induced hepatitis. J. Immunol. 160(8), 4082-4089 (1998).
39. Chen YL, Yu CK, Lei HY. Propionibacterium acnes induces acute TNFα-mediated apoptosis of hepatocytes followed by inflammatory T-cell-mediated granulomatous hepatitis in mice. J. Biomed. Sci. 6(5), 349-356 (1999).
40. + regulatory T cells in persistent human viral infections. Hum. Immunol. 69(11), 771-775 (2008).
41. Dolganiuc A, Szabo G. T cells with regulatory activity in hepatitis C virus infection: what we know and what we don't. J. Leukoc. Biol. 84(3), 614-622 (2008).
42. Kanto T, Hayashi N. Immunopathogenesis of hepatitis C virus infection: multifaceted strategies subverting innate and adaptive immunity. Intern. Med. 45(4), 183-191 (2006).
43. Thio CL. Host genetic factors and antiviral immune responses to hepatitis C virus. Clin. Liver Dis. 12(3), 713-726, xi (2008).
44. Neuman MG, Sha K, Esguerra R et al. Inflammation and repair in viral hepatitis C. Dig. Dis. Sci. 53(6), 1468-1487 (2008).
45. Ramadori G, Saile B. Inflammation, damage repair, immune cells, and liver fibrosis: specific or nonspecific, this is the question. Gastroenterology 127(3), 997-1000 (2004).
46. Ramadori G, Saile B. Portal tract fibrogenesis in the liver. Lab. Invest. 84(2), 153-159 (2004).
47. Wietzke P, Braun F, Ringe B, Ramadori G. Interferon α-2A and ribavirin therapy for hepatitis C recurrence after liver transplantation. Transplant. Proc. 32(7), 2539-2542 (2000).
48. Cohen J. The scientific challenge of hepatitis C. Science 285(5424), 26-30 (1999).
49. Choo QL, Richman KH, Han JH et al. Genetic organization and diversity of the hepatitis C virus. Proc. Natl Acad. Sci. USA 88(6), 2451-2455 (1991).
50. Hijikata M, Kato N, Ootsuyama Y, Nakagawa M, Shimotohno K. Gene mapping of the putative structural region of the hepatitis C virus genome by in vitro processing analysis. Proc. Natl Acad. Sci. USA 88(13), 5547-5551 (1991).
51. Santolini E, Migliaccio G, La Monica N. Biosynthesis and biochemical properties of the hepatitis C virus core protein. J. Virol. 68(6), 3631-3641 (1994).
52. Shimotohno K, Tanji Y, Hirowatari Y, Komoda Y, Kato N, Hijikata M. Processing of the hepatitis C virus precursor protein. J. Hepatol. 22(1), 87-92 (1995).
53. Mizushima H, Hijikata M, Tanji Y, Kimura K, Shimotohno K. Analysis of N-terminal processing of hepatitis C virus nonstructural protein 2. J. Virol. 68(4), 2731-2734 (1994).
54. Hijikata M, Mizushima H, Akagi T et al. Two distinct proteinase activities required for the processing of a putative nonstructural precursor protein of hepatitis C virus. J. Virol. 67(8), 4665-4675 (1993).
55. Grakoui A, McCourt DW, Wychowski C, Feinstone SM, Rice CM. A second hepatitis C virus-encoded proteinase. Proc. Natl Acad. Sci. USA 90(22), 10583-10587 (1993).
56. Tomei L, Failla C, Santolini E, De Francesco R, La Monica N. NS3 is a serine protease required for processing of hepatitis C virus polyprotein. J. Virol. 67(7), 4017-4026 (1993).
57. Bartenschlager R, Ahlborn-Laake L, Mous J, Jacobsen H. Nonstructural protein 3 of the hepatitis C virus encodes a serine-type proteinase required for cleavage at the NS3/4 and NS4/5 junctions. J. Virol. 67(7), 3835-3844 (1993).
58. Wang C, Siddiqui A. Structure and function of the hepatitis C virus internal ribosome entry site. Curr. Top. Microbiol. Immunol. 203, 99-115 (1995).
59. Irshad M, Dhar I. Hepatitis C virus core protein: an update on its molecular biology, cellular functions and clinical implications. Med. Princ. Pract. 15(6), 405-416 (2006).
60. Moradpour D, Penin F, Rice CM. Replication of hepatitis C virus. Nat. Rev. 5(6), 453-463 (2007).
61. Boulant S, Montserret R, Hope RG et al. Structural determinants that target the hepatitis C virus core protein to lipid droplets. J. Biol. Chem. 281(31), 22236-22247 (2006).
62. Asselah T, Rubbia-Brandt L, Marcellin P, Negro F. Steatosis in chronic hepatitis C: why does it really matter? Gut 55(1), 123-130 (2006).
63. Bartosch B, Cosset FL. Cell entry of hepatitis C virus. Virology 348(1), 1-12 (2006).
64. Cocquerel L, Voisset C, Dubuisson J. Hepatitis C virus entry: potential receptors and their biological functions. J. Gen. Virol. 87(Pt 5), 1075-1084 (2006).
65. Wakita T, Pietschmann T, Kato T et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat. Med. 11(7), 791-796 (2005).
66. Dubuisson J, Penin F, Moradpour D. Interaction of hepatitis C virus proteins with host cell membranes and lipids. Trends Cell Biol. 12(11), 517-523 (2002).
67. Helle F, Wychowski C, Vu-Dac N, Gustafson KR, Voisset C, Dubuisson J. Cyanovirin-N inhibits hepatitis C virus entry by binding to envelope protein glycans. J. Biol. Chem. 281(35), 25177-25183 (2006).
68. Pileri P, Uematsu Y, Campagnoli S et al. Binding of hepatitis C virus to CD81. Science 282(5390), 938-941 (1998).
69. Scarselli E, Ansuini H, Cerino R et al. The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J. 21(19), 5017-5025 (2002).
70. Barth H, Schafer C, Adah MI et al. Cellular binding of hepatitis C virus envelope glycoprotein E2 requires cell surface heparan sulfate. J. Biol. Chem. 278(42), 41003-41012 (2003).
71. Gardner JP, Durso RJ, Arrigale RR et al. L-SIGN (CD 209L) is a liver-specific capture receptor for hepatitis C virus. Proc. Natl Acad. Sci. USA 100(8), 4498-4503 (2003).
72. Lozach PY, Lortat-Jacob H, de Lacroix de Lavalette A et al. DC-SIGN and L-SIGN are high affinity binding receptors for hepatitis C virus glycoprotein E2. J. Biol. Chem. 278(22), 20358-20366 (2003).
73. Agnello V, Abel G, Elfahal M, Knight GB, Zhang QX. Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. Proc. Natl Acad. Sci. USA 96(22), 12766-12771 (1999).
74. Monazahian M, Bohme I, Bonk S et al. Low density lipoprotein receptor as a candidate receptor for hepatitis C virus. J. Med. Virol. 57(3), 223-229 (1999).
75. Carrere-Kremer S, Montpellier-Pala C, Cocquerel L, Wychowski C, Penin F, Dubuisson J. Subcellular localization and topology of the p7 polypeptide of hepatitis C virus. J. Virol. 76(8), 3720-3730 (2002).
76. Lin C, Lindenbach BD, Pragai BM, McCourt DW, Rice CM. Processing in the hepatitis C virus E2-NS2 region: identification of p7 and two distinct E2-specific products with different C termini. J. Virol. 68(8), 5063-5073 (1994).
77. Clarke D, Griffin S, Beales L et al. Evidence for the formation of a heptameric ion channel complex by the hepatitis C virus p7 protein in vitro. J. Biol. Chem. 281(48), 37057-37068 (2006).
78. Sakai A, Claire MS, Faulk K et al. The p7 polypeptide of hepatitis C virus is critical for infectivity and contains functionally important genotype-specific sequences. Proc. Natl Acad. Sci. USA 100(20), 11646-11651 (2003).
79. Griffin SD, Beales LP, Clarke DS et al. The p7 protein of hepatitis C virus forms an ion channel that is blocked by the antiviral drug, amantadine. FEBS Lett. 535(1-3), 34-38 (2003).
80. Steinmann E, Penin F, Kallis S, Patel AH, Bartenschlager R, Pietschmann T. Hepatitis C virus p7 protein is crucial for assembly and release of infectious virions. PLoS Pathog. 3(7), e103 (2007).
81. Liu Q, Bhat RA, Prince AM, Zhang P. The hepatitis C virus NS2 protein generated by NS2-3 autocleavage is required for NS5A phosphorylation. Biochem. Biophys. Res. Commun. 254(3), 572-577 (1999).
82. Dumoulin FL, von dem Bussche A, Li J et al. Hepatitis C virus NS2 protein inhibits gene expression from different cellular and viral promoters in hepatic and nonhepatic cell lines. Virology 305(2), 260-266 (2003).
83. Kaukinen P, Sillanpaa M, Kotenko S et al. Hepatitis C virus NS2 and NS3/4A proteins are potent inhibitors of host cell cytokine/ chemokine gene expression. Virol. J. 3, 66 (2006).
84. Lindenbach BD, Evans MJ, Syder AJ et al. Complete replication of hepatitis C virus in cell culture. Science 309(5734), 623-626 (2005).
85. Jones CT, Murray CL, Eastman DK, Tassello J, Rice CM. Hepatitis C virus p7 and NS2 proteins are essential for production of infectious virus. J. Virol. 81(16), 8374-8383 (2007).
86. Kim JL, Morgenstern KA, Lin C et al. Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide. Cell 87(2), 343-355 (1996).
87. Love RA, Parge HE, Wickersham JA et al. The crystal structure of hepatitis C virus NS3 proteinase reveals a trypsin-like fold and a structural zinc binding site. Cell 87(2), 331-342 (1996).
88. Lindenbach BD, Rice CM. Unravelling hepatitis C virus replication from genome to function. Nature 436(7053), 933-938 (2005).
89. Foy E, Li K, Wang C et al. Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. Science 300(5622), 1145-1148 (2003).
90. Meylan E, Curran J, Hofmann K et al. Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature 437(7062), 1167-1172 (2005).
91. Sen GC, Sarkar SN. Hitching RIG to action. Nat. Immunol. 6(11), 1074-1076 (2005).
92. Li XD, Sun L, Seth RB, Pineda G, Chen ZJ. Hepatitis C virus protease NS3/ 4A cleaves mitochondrial antiviral signaling protein off the mitochondria to evade innate immunity. Proc. Natl Acad. Sci. USA 102(49), 17717-17722 (2005).
93. Li K, Foy E, Ferreon JC et al. Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. Proc. Natl Acad. Sci. USA 102(8), 2992-2997 (2005).
94. Elazar M, Liu P, Rice CM, Glenn JS. An N-terminal amphipathic helix in hepatitis C virus (HCV) NS4B mediates membrane association, correct localization of replication complex proteins, and HCV RNA replication. J. Virol. 78 (20), 11393-11400 (2004).
95. Paredes AM, Blight KJ. A genetic interaction between hepatitis C virus NS4B and NS3 is important for RNA replication. J. Virol 82(21), 10671-10683 (2008).
96. Jones DM, Patel AH, Targett Adams P, McLauchlan J. The hepatitis C virus NS4B protein can trans-complement viral RNA replication and modulates production of infectious virus. J. Virol. 83(5), 2163-2177 (2009).
97. Penin F, Brass V, Appel N et al. Structure and function of the membrane anchor domain of hepatitis C virus nonstructural protein 5A. J. Biol. Chem. 279(39), 40835-40843 (2004).
98. Tanji Y, Kaneko T, Satoh S, Shimotohno K. Phosphorylation of hepatitis C virus-encoded nonstructural protein NS5A. J. Virol. 69(7), 3980-3986 (1995).
99. Tellinghuisen TL, Marcotrigiano J, Gorbalenya AE, Rice CM. The NS5A protein of hepatitis C virus is a zinc metalloprotein. J. Biol. Chem. 279(47), 48576-48587 (2004).
100. Tellinghuisen TL, Marcotrigiano J, Rice CM. Structure of the zinc-binding domain of an essential component of the hepatitis C virus replicase. Nature 435(7040), 374-379 (2005).
101. Gale M Jr, Blakely CM, Kwieciszewski B et al. Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein: molecular mechanisms of kinase regulation. Mol. Cell. Biol. 18(9), 5208-5218 (1998).
102. Gale MJ Jr, Korth MJ, Katze MG. Repression of the PKR protein kinase by the hepatitis C virus NS5A protein: a potential mechanism of interferon resistance. Clin. Diagn. Virol. 10(2-3), 157-162 (1998).
103. Gale MJ Jr, Korth MJ, Tang NM et al. Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein. Virology 230(2), 217-227 (1997).
104. Appel N, Pietschmann T, Bartenschlager R. Mutational analysis of hepatitis C virus nonstructural protein 5A: potential role of differential phosphorylation in RNA replication and identification of a genetically flexible domain. J. Virol. 79(5), 3187-3194 (2005).
105. Tellinghuisen TL, Foss KL, Treadaway J. Regulation of hepatitis C virion production via phosphorylation of the NS5A protein. PLoS Pathog. 4(3), e1000032 (2008).
106. Appel N, Zayas M, Miller S et al. Essential role of domain III of nonstructural protein 5A for hepatitis C virus infectious particle assembly. PLoS Pathog. 4(3), e1000035 (2008).
107. Ivashkina N, Wolk B, Lohmann V et al. The hepatitis C virus RNA-dependent RNA polymerase membrane insertion sequence is a transmembrane segment. J. Virol. 76(24), 13088-13093 (2002).
108. Schmidt-Mende J, Bieck E, Hugle T et al. Determinants for membrane association of the hepatitis C virus RNA-dependent RNA polymerase. J. Biol. Chem. 276(47), 44052-44063 (2001).
109. Bartenschlager R, Frese M, Pietschmann T. Novel insights into hepatitis C virus replication and persistence. Adv. Virus Res. 63, 71-180 (2004).
110. Bressanelli S, Tomei L, Roussel A et al. Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. Proc. Natl Acad. Sci. USA 96(23), 13034-13039 (1999).
111. Lesburg CA, Cable MB, Ferrari E, Hong Z, Mannarino AF, Weber PC. Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site. Nat. Struct. Biol. 6(10), 937-943 (1999).
112. Otto GA, Puglisi JD. The pathway of HCV IRES-mediated translation initiation. Cell 119(3), 369-380 (2004).
113. Pestova TV, Kolupaeva VG, Lomakin IB et al. Molecular mechanisms of translation initiation in eukaryotes. Proc. Natl Acad. Sci. USA 98(13), 7029-7036 (2001).
114. Ji H, Fraser CS, Yu Y, Leary J, Doudna JA. Coordinated assembly of human translation initiation complexes by the hepatitis C virus internal ribosome entry site RNA. Proc. Natl Acad. Sci. USA 101(49), 16990-16995 (2004).
115. Barth H, Liang TJ, Baumert TF. Hepatitis C virus entry: molecular biology and clinical implications. Hepatology 44(3), 527-535 (2006).
116. Evans MJ, von Hahn T, Tscherne DM et al. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature 446(7137), 801-805 (2007).
117. Levine RA. Treating histologically mild chronic hepatitis C: monotherapy, combination therapy, or tincture of time? Ann. Intern. Med. 129(4), 323-326 (1998).
118. Foster GR, Goldin RD, Main J, Murray-Lyon I, Hargreaves S, Thomas HC. Management of chronic hepatitis C: clinical audit of biopsy based management algorithm. BMJ 315(7106), 453-458 (1997).
119. Wong JB, Koff RS. Watchful waiting with periodic liver biopsy versus immediate empirical therapy for histologically mild chronic hepatitis C. A cost-effectiveness analysis. Ann. Intern. Med. 133(9), 665-675 (2000).
120. Di Bisceglie AM, Martin P, Kassianides C et al. Recombinant interferon α therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N. Engl. J. Med. 321(22), 1506-1510 (1989).
121. Davis GL, Balart LA, Schiff ER et al. Treatment of chronic hepatitis C with recombinant interferon α. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. N. Engl. J. Med. 321(22), 1501-1506 (1989).
122. Poynard T, Leroy V, Cohard M et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology 24(4), 778-789 (1996).
123. Davis GL, Esteban-Mur R, Rustgi V et al. Interferon α-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N. Engl. J. Med. 339(21), 1493-1499 (1998).
124. Poynard T, Marcellin P, Lee SS et al. Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 352(9138), 1426-1432 (1998).
125. Poynard T, McHutchison J, Davis GL et al. Impact of interferon α-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C. Hepatology 32(5), 1131-1137 (2000).
126. Baffis V, Shrier I, Sherker AH, Szilagyi A. Use of interferon for prevention of hepatocellular carcinoma in cirrhotic patients with hepatitis B or hepatitis C virus infection. Ann. Intern. Med. 131(9), 696-701 (1999).
127. Mihm S, Hartmann H, Fayyazi A, Ramadori G. Preferential virological response to interferon-α2a in patients with chronic hepatitis C infected by virus genotype 3a and exhibiting a low γ-GT/ALT ratio. Dig. Dis. Sci. 41(6), 1256-1264 (1996).
128. Mihm S, Monazahian M, Grethe S, Fechner C, Ramadori G, Thomssen R. Ratio of serum γ-GT/ALT rather than ISDR variability is predictive for initial virological response to IFN-α in chronic HCV infection. J. Med. Virol. 58(3), 227-234 (1999).
129. Fukuma T, Enomoto N, Marumo F, Sato C. Mutations in the interferon-sensitivity determining region of hepatitis C virus and transcriptional activity of the nonstructural region 5A protein. Hepatology 28(4), 1147-1153 (1998).
130. Mihm S, Monazahian M, Grethe S, Meier V, Thomssen R, Ramadori G. Lack of clinical evidence for involvement of hepatitis C virus interferon-α sensitivity-determining region variability in RNA-dependent protein kinase-mediated cellular antiviral responses. J. Med. Virol. 61(1), 29-36 (2000).
131. Wietzke-Braun P, Maouzi AB, Manhardt LB, Bickeboller H, Ramadori G, Mihm S. Interferon regulatory factor-1 promoter polymorphism and the outcome of hepatitis C virus infection. Eur. J. Gastroenterol. Hepatol. 18(9), 991-997 (2006).
132. Wietzke-Braun P, Manhardt LB, Rosenberger A, Uy A, Ramadori G, Mihm S. Spontaneous elimination of hepatitis C virus infection: a retrospective study on demographic, clinical, and serological correlates. World J. Gastroenterol. 13(31), 4224-4229 (2007).
133. Wietzke P, Schott P, Braun F, Mihm S, Ramadori G. Clearance of HCV RNA in a chronic hepatitis C virus-infected patient during acute hepatitis B virus superinfection. Liver 19(4), 348-353 (1999).
134. Berg T, von Wagner M, Nasser S et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-α-2a plus ribavirin. Gastroenterology 130(4), 1086-1097 (2006).
135. 2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology 131(2), 451-460 (2006).
136. Zeuzem S, Buti M, Ferenci P et al. Efficacy of 24 weeks treatment with peginterferon α-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J. Hepatol. 44(1), 97-103 (2006).
137. Mangia A, Santoro R, Minerva N et al. Peginterferon α-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N. Engl. J. Med. 352(25), 2609-2617 (2005).
138. von Wagner M, Huber M, Berg T et al. Peginterferon-α-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 129(2), 522-527 (2005).
139. Shiffman ML, Suter F, Bacon BR et al. Peginterferon α-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N. Engl. J. Med. 357(2), 124-134 (2007).
140. Zeuzem S, Hultcrantz R, Bourliere M et al. Peginterferon α-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J. Hepatol. 40(6), 993-999 (2004).
141. Di Bisceglie AM, Shiffman ML, Everson GT et al. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N. Engl. J. Med. 359(23), 2429-2441 (2008).
142. Jacobson IM, Brown RS Jr, Freilich B et al. Peginterferon α-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial. Hepatology 46(4), 971-981 (2007).
143. Hadziyannis SJ, Sette H Jr, Morgan TR et al. Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann. Intern. Med. 140(5), 346-355 (2004).
144. Hayashi N, Takehara T. Antiviral therapy for chronic hepatitis C: past, present, and future. J. Gastroenterol. 41(1), 17-27 (2006).
145. Der SD, Zhou A, Williams BR, Silverman RH. Identification of genes differentially regulated by interferon α, β, or γ using oligonucleotide arrays. Proc. Natl Acad. Sci. USA 95(26), 15623-15628 (1998).
146. Haller O, Frese M, Kochs G. Mx proteins: mediators of innate resistance to RNA. viruses. Rev. Sci. Tech. 17(1), 220-230 (1998).
147. Takaoka A, Yanai H. Interferon signalling network in innate defence. Cell. Microbiol. 8(6), 907-922 (2006).
148. Frese M, Pietschmann T, Moradpour D, Haller O, Bartenschlager R. Interferon-α inhibits hepatitis C virus subgenomic RNA replication by an MxA-independent pathway. J. Gen. Virol. 82(Pt 4), 723-733 (2001).
149. Meier V, Mihm S, Ramadori G. mxA gene expression in peripheral blood mononuclear cells from patients infected chronically with hepatitis C virus treated with interferon-α. J. Med. Virol. 62(3), 318-326 (2000).
150. Feld JJ, Nanda S, Huang Y et al. Hepatic gene expression during treatment with peginterferon and ribavirin: identifying molecular pathways for treatment response. Hepatology 46(5), 1548-1563 (2007).
151. Sarasin-Filipowicz M, Oakeley EJ, Duong FH et al. Interferon signaling and treatment outcome in chronic hepatitis C. Proc. Natl Acad. Sci. USA 105(19), 7034-7039 (2008).
152. Meier V, Mihm S, Ramadori G. Interferon-α therapy does not modulate hepatic expression of classical type I interferon inducible genes. J. Med. Virol. 80(11), 1912-1918 (2008).
153. Lanford RE, Guerra B, Lee H, Chavez D, Brasky KM, Bigger CB. Genomic response to interferon-α in chimpanzees: implications of rapid downregulation for hepatitis C kinetics. Hepatology 43(5), 961-972 (2006).
154. Lanford RE, Guerra B, Bigger CB, Lee H, Chavez D, Brasky KM. Lack of response to exogenous interferon-α in the liver of chimpanzees chronically infected with hepatitis C virus. Hepatology 46(4), 999-1008 (2007).
155. Mihm S, Frese M, Meier V et al. Interferon type I gene expression in chronic hepatitis C. Lab. Invest. 84(9), 1148-1159 (2004).
156. Patzwahl R, Meier V, Ramadori G, Mihm S. Enhanced expression of interferon-regulated genes in the liver of patients with chronic hepatitis C virus infection: detection by suppression-subtractive hybridization. J. Virol. 75(3), 1332-1338 (2001).
157. Shackel NA, McGuinness PH, Abbott CA, Gorrell MD, McCaughan GW. Insights into the pathobiology of hepatitis C virus-associated cirrhosis: analysis of intrahepatic differential gene expression. Am. J. Pathol. 160(2), 641-654 (2002).
158. MacQuillan GC, Mamotte C, Reed WD, Jeffrey GP, Allan JE. Upregulation of endogenous intrahepatic interferon stimulated genes during chronic hepatitis C virus infection. J. Med. Virol. 70(2), 219-227 (2003).
159. Wright TL. Treatment of patients with hepatitis C and cirrhosis. Hepatology 36(5 Suppl. 1), S185-S194 (2002).
160. Bruno S, Stroffolini T, Colombo M et al. Sustained virological response to interferon-α is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology 45(3), 579-587 (2007).
161. Hung CH, Lee CM, Lu SN et al. Long-term effect of interferon α-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis. J. Viral Hepat. 13(6), 409-414 (2006).
162. Camma C, Giunta M, Andreone P, Craxi A. Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach. J. Hepatol. 34(4), 593-602 (2001).
163. Papatheodoridis GV, Papadimitropoulos VC, Hadziyannis SJ. Effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a meta-analysis. Aliment. Pharmacol. Ther. 15(5), 689-698 (2001).
164. Hofer H, Watkins-Riedel T, Janata O et al. Spontaneous viral clearance in patients with acute hepatitis C can be predicted by repeated measurements of serum viral load. Hepatology 37(1), 60-64 (2003).
165. Gerlach JT, Diepolder HM, Zachoval R et al. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology 125(1), 80-88 (2003).
166. 2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response. Gastroenterology 130(3), 632-638 (2006).
167. Santantonio T, Fasano M, Sinisi E et al. Efficacy of a 24-week course of PEG-interferon α-2b monotherapy in patients with acute hepatitis C after failure of spontaneous clearance. J. Hepatol. 42(3), 329-333 (2005).
168. Kamal SM, Moustafa KN, Chen J et al. Duration of peginterferon therapy in acute hepatitis C: a randomized trial. Hepatology 43(5), 923-931 (2006).
169. Liu C, Zhu H, Subramanian GM, Moore PA, Xu Y, Nelson DR. Anti-hepatitis C virus activity of albinterferon α-2b in cell culture. Hepatol. Res. 37(11), 941-947 (2007).
170. Bain VG, Kaita KD, Yoshida EM et al. A Phase 2 study to evaluate the antiviral activity, safety, and pharmacokinetics of recombinant human albumin - interferon α fusion protein in genotype 1 chronic hepatitis C patients. J. Hepatol. 44(4), 671-678 (2006).
171. Balan V, Nelson DR, Sulkowski MS et al. A Phase I/II study evaluating escalating doses of recombinant human albumin - interferon-α fusion protein in chronic hepatitis C patients who have failed previous interferon-α-based therapy. Antivi. Ther. 11(1), 35-45 (2006).
172. Zeuzem S, Yoshida EM, Benhamou Y et al. Albinterferon α-2b dosed every two or four weeks in interferon-naive patients with genotype 1 chronic hepatitis C. Hepatology 48(2), 407-417 (2008).
173. Bain VG, Kaita KD, Marotta P et al. Safety and antiviral activity of albinterferon α-2b dosed every four weeks in genotype 2/3 chronic hepatitis C patients. Clin. Gastroenterol. Hepatol. 6(6), 701-706 (2008).
174. Nelson DR, Rustgi V, Balan V et al. Safety and antiviral activity of albinterferon α-2b in prior interferon nonresponders with chronic hepatitis C. Clin. Gastroenterol. Hepatol. 7(2), 212-218 (2009).
175. Novozhenov V, Zakharova N, Vinogradova E et al. Phase 2 study of ω interferon alone or in combination with ribavirin in subjects with chronic hepatitis C genotype-1 infection. J. Hepatol.
176. De Leede LG, Humphries JE, Bechet AC, Van Hoogdalem EJ, Verrijk R, Spencer DG. Novel controlled-release Lemna-derived IFN-α2b (Locteron): pharmacokinetics, pharmacodynamics, and tolerability in a Phase I clinical trial. J. Interferon Cytokine Res. 28(2), 113-122 (2008).
177. Wu JZ, Lin CC, Hong Z. Ribavirin, viramidine and adenosine-deaminase-catalysed drug activation: implication for nucleoside prodrug design. J. Antimicrob. Chemother. 52(4), 543-546 (2003).
178. Wu JZ, Walker H, Lau JY, Hong Z. Activation and deactivation of a broad-spectrum antiviral drug by a single enzyme: adenosine deaminase catalyzes two consecutive deamination reactions. Antimicrob. Agents Chemother. 47(1), 426-431 (2003).
179. 14C]ribavirin in rat and monkey red blood cells and liver. Antimicrob. Agents Chemother. 48(5), 1872-1875 (2004).
180. Gish RG, Arora S, Rajender Reddy K et al. Virological response and safety outcomes in therapy-naive patients treated for chronic hepatitis C with taribavirin or ribavirin in combination with pegylated interferon α-2a: a randomized, Phase 2 study. J. Hepatol. 47(1), 51-59 (2007).
181. Pockros P, Jacobsen IM, Bacon BR et al. Taribavirin exposure analysis from a previous Phase 3 trial correlates with Phase 2b weight based dosing interim results. Hepatology 48 (Suppl. 1), 1857A (2008).
182. Hinrichsen H, Benhamou Y, Wedemeyer H et al. Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. Gastroenterology 127(5), 1347-1355 (2004).
183. Lu L, Pilot-Matias TJ, Stewart KD et al. Mutations conferring resistance to a potent hepatitis C virus serine protease inhibitor in vitro. Antimicrob. Agents Chemother. 48(6), 2260-2266 (2004).
184. Reesink HW, Zeuzem S, Weegink CJ et al. Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a Phase Ib, placebo-controlled, randomized study. Gastroenterology 131(4), 997-1002 (2006).
185. Sarrazin C, Kieffer TL, Bartels D et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 132(5), 1767-1777 (2007).
186. Forestier N, Reesink HW, Weegink CJ et al. Antiviral activity of telaprevir (VX-950) and peginterferon α-2a in patients with hepatitis C. Hepatology 46(3), 640-648 (2007).
187. Les L. Interim results presented at EASL from PROVE 1 clinical trial of investigational drug telaprevir in patients with genotype 1 hepatitis C. Gastroenterology 132(7), 2283-2284 (2007).
188. Forns X, Marcellin P, Goeser T et al. Phase 2 study of telaprevir administered q8h or q12h with peginterferon-α-2a or - α-2b and ribavirin in treatment-naïve subjects with genotype 1 hepatitis C: week 4 interim results. Hepatology 48(Suppl. 1), 1854A (2008).
189. Shiffman ML, Berg T, Poordad F et al. A study of telaprevir combined with peginterferon-α-2a and ribavirin in subjects with well-documented non-response or relapse after previous peginterferon-α-2a and ribavirin treatment: interim analysis. Hepatology 48(Suppl. 1), 1852A (2008).
190. Mederacke I, Wedemeyer H, Manns MP. Boceprevir, an NS3 serine protease inhibitor of hepatitis C virus, for the treatment of HCV infection. Curr. Opin. Investig. Drugs 10(2), 181-189 (2009).
191. Malcolm BA, Liu R, Lahser F et al. SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of α interferon in replicon cells. Antimicrob. Agents Chemother. 50(3), 1013-1020 (2006).
192. Sarrazin C, Rouzier R, Wagner F et al. SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon α-2b for genotype 1 nonresponders. Gastroenterology 132(4), 1270-1278 (2007).
193. Kwo PY, Lawitz E, McCone J et al. HCV SPRINT-1: boceprevir plus peginterferon α-2b/ribavirin for treatment of genotype 1 chronic hepatitis C in previously untreated patients. Hepatology 48(Suppl. 1), LB16 (2008).
194. Seiwert SD, Andrews SW, Jiang Y et al. Preclinical characteristics of the HCV NS3/4A protease inhibitor ITMN-191 (R7227). Antimicrob. Agents Chemother. 52(12), 4432-4441 (2008).
195. Rajagopalan R, Misialek S, Stevens S et al. Inhibition and binding kinetics of the hepatitis C virus NS3 protease inhibitor ITMN-191 reveals tight binding and slow dissociative behavior. Biochemistry (2009).
196. Forestier N, Larrey D, Guyader D et al. treatment of chronic hepatitis C virus (HCV) genotype 1 patients with the NS3/4A protease inhibitor ITMN-191 leads to rapid reductions in plasma HCV RNA: results of a Phase 1B multiple ascending dose (MAD) study. Hepatology 48(Suppl. 1), 1847A (2008).
197. Tan H, Rajyaguru S, Wu T et al. Combination of the NS3/4A protease inhibitor ITMN-191 (R7227) with the active moiety of the NS5b inhibitors R1626 or R7128 enhances replicon clearance and reduces the emergence of drug resistant variants. Hepatology 48(Suppl. 1), 1885A (2008).
198. Yang W, Zhao Y, Fabrycki J et al. Selection of replicon variants resistant to ACH-806, a novel hepatitis C virus inhibitor with no cross-resistance to NS3 protease and NS5B polymerase inhibitors. Antimicrob. Agents Chemother. 52(6), 2043-2052 (2008).
199. Manns MP, Bourliere M, Benhamou Y et al. Safety and antiviral activity of bi201335, a new HCV NS3 protease inhibitor, in treatment naive patients with chronic hepatitis C genotype-1 infection given as monotherapy and in combination with peginterferon α 2a (P) and ribavirin (R). Hepatology 48 (Suppl. 1), 1849A (2008).
200. Lin TI, Lenz O, Fanning G et al. In vitro activity and pre-clinical profile of TMC435350, a potent HCV protease inhibitor. Antimicrob. Agents Chemother. (2009).
201. Verloes R, Farha KA, van Vliet A et al. results of a Phase I placebo-controlled trial in healthy volunteers to examine the safety, tolerability and pharmacokinetics of the HCV protease inhibitor TMC435350 after single and repeated dosing. Hepatology 46(Suppl. 1), 1318A (2007).
202. Reesink H, Verloes R, Abou Farha K et al. Safety of the HCV protease inhibitor TMC435350 in healthy volunteers and safety and activity in chronic hepatitis C infected individuals: a Phase I study. J. Hepatol. 48 (Suppl. 2), S28 (2008).
203. Godofsky E, Afdhal N, Rustgi V et al. First clinical results for a novel antiviral treatment for hepatitis C: a Phase I/II dose escalation trial assessing, tolerance, pharmacokinetics, and antiviral activity of NM283. J. Hepatol. 40(Suppl. 1), S35 (2004).
204. Afdhal N, O Brien C, Godofsky E et al. Valopicitabine (NM283), alone or with peginterferon, compared to peg interferon/ribavirin (pegifn/RBV) re-treatment in hepatitis patients with prior non-response to PEGIFN/RBV: week 24 results. J. Hepatol. 44(Suppl. 2), S19 (2006).
205. Afdhal N, O'Brien C, Godofsky E et al. Valopicitabine (NM283), alone or with peg-interferon, compared to peg interferon/ribavirin (PEGIFN/RBV) retreatment in patients with HCV-1 infection and prior non-response to PEGIFN/RBV: one-year results. J. Hepatol. 46(Suppl. 1), S5 (2007).
206. Klumpp K, Leveque V, Le Pogam S et al. The novel nucleoside analog R1479 (4′-azidocytidine) is a potent inhibitor of NS5B-dependent RNA synthesis and hepatitis C virus replication in cell culture. J. Biol. Chem. 281(7), 3793-3799 (2006).
207. Roberts SK, Cooksley G, Dore GJ et al. Robust antiviral activity of R1626, a novel nucleoside analog: a randomized, placebo-controlled study in patients with chronic hepatitis C. Hepatology 48(2), 398-406 (2008).
208. Pockros PJ, Nelson D, Godofsky E et al. R1626 plus peginterferon α-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin. Hepatology 48(2), 385-397 (2008).
209. Villano SA, Raible D, Harper D et al. Antiviral activity of the non-nucleoside polymerase inhibitor, HCV-796, in combination with pegylated interferon α-2b in treatment-naive patients with chronic HCV. J. Hepatol. 46(Suppl. 1), S24 (2007).
210. Bavisotto L, Wang CC, Jacobsen IM et al. Antiviral, pharmacokinetic and safety data for GS-9190, a non-nucleoside HCV NS5B polymerase inhibitor, in a phase-1 trial in HCV genotype 1 infected subjects. Hepatology 46(4), 49A (2007).
211. Erhardt A, Wedemeyer H, Benhamou Y et al. Safety, pharmacokinetics and antiviral effect of BILB1941, a novel HCV RNA polymerase inhibitor, after 5 days oral treatment in patients with chronic hepatitis C. J. Hepatol. 46(Suppl. 1), S222 (2007).
212. Li H, Tatlock J, Linton A et al. Discovery of (R)-6-cyclopentyl-6-(2-(2,6-diethylpyridin-4-yl)ethyl)-3- ((5,7-dimethyl-[1,2,4] triazolo[1,5-a]pyrimidin-2-yl)methyl)- 4-hydroxy-5,6-dihydropyran-2-on e (PF-00868554) as a potent and orally available hepatitis C virus polymerase inhibitor. J. Med. Chem. (2009) (In Press).
213. Hammond J, Rosario MC, Wagner F et al. Antiviral activity of the HCV polymerase inhibitor PF-00868554 administered as monotherapy in HCV genotype 1 infected subjects. Hepatology 48(Suppl. 1), LB11 (2008).
214. Rahimy MH, Crowley CA, Freddo L, Sergeeva MV, Golec B. Results of a Phase I safety, tolerability and pharmacokinetic study of ANA598, a nonnucleoside NS5B polymerase inhibitor, in healthy volunteers. Hepatology 48(Suppl. 1), LB13 (2008).
215. Nettles R, Chien C, Chun E et al. BMS-790052 is a First-in-class potent hepatitis C virus (HCV) NS5A inhibitor for patients with chronic HCV infection: results from a proof-of-concept study. Hepatology 48(Suppl. 1), LB12 (2008).
216. Kaita K, Yoshida E, Kunimoto D et al. Proof of concept study of celgosivir in combination with peginterferon α-2b and ribavirin in chronic hepatitis c genotype-1 non-responder patients. J. Hepatol. 46(Suppl. 1), S56-S57 (2007).
217. Handschumacher RE, Harding MW, Rice J, Drugge RJ, Speicher DW. Cyclophilin: a specific cytosolic binding protein for cyclosporin A. Science 226(4674), 544-547 (1984).
218. Liu J, Farmer JD Jr, Lane WS, Friedman J, Weissman I, Schreiber SL. Calcineurin is a common target of cyclophilin - cyclosporin A and FKBP-FK506 complexes. Cell 66(4), 807-815 (1991).
219. Nakagawa M, Sakamoto N, Tanabe Y et al. Suppression of hepatitis C virus replication by cyclosporin a is mediated by blockade of cyclophilins. Gastroenterology 129(3), 1031-1041 (2005).
220. Watashi K, Ishii N, Hijikata M et al. Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase. Mol. Cell 19(1), 111-122 (2005).
221. Robida JM, Nelson HB, Liu Z, Tang H. Characterization of hepatitis C virus subgenomic replicon resistance to cyclosporine in vitro. J. Virol. 81(11), 5829-5840 (2007).
222. Paeshuyse J, Kaul A, De Clercq E et al. The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro. Hepatology 43(4), 761-770 (2006).
223. Ishii N, Watashi K, Hishiki T et al. Diverse effects of cyclosporine on hepatitis C virus strain replication. J. Virol. 80(9), 4510-4520 (2006).
224. Heitman J, Cullen BR. Cyclophilin B escorts the hepatitis C virus RNA polymerase: a viral achilles heel? Mol. Cell 19(2), 145-146 (2005).
225. Goto K, Watashi K, Murata T, Hishiki T, Hijikata M, Shimotohno K. Evaluation of the anti-hepatitis C virus effects of cyclophilin inhibitors, cyclosporin A, and NIM811. Biochem. Biophys. Res. Commun. 343(3), 879-884 (2006).
226. Watashi K, Shimotohno K. Chemical genetics approach to hepatitis C virus replication: cyclophilin as a target for anti-hepatitis C virus strategy. Rev. Med. Virol. 17(4), 245-252 (2007).
227. Inoue K, Umehara T, Ruegg UT et al. Evaluation of a cyclophilin inhibitor in hepatitis C virus-infected chimeric mice in vivo. Hepatology 45(4), 921-928 (2007).
228. Flisiak R, Horban A, Gallay P et al. The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus. Hepatology 47(3), 817-826 (2008).
229. Herrmann E, Flisiak R, Horban A et al. Viral kinetics during 14-day treatment with DEBIO-025 demonstrate efficient blocking of viral replication in different HCV genotypes without signs of emerging viral resistance. J. Hepatol. 46(Suppl. 1), S40 (2007).